Effects of haloperidol on rat behavior and density of dopaminergic D2-like receptors

Behavioural Processes

Volumn 63, Issue 1, 2003, Pages 45-52

  Vasconcelos, Silvânia M M ^a   Nascimento, Viviane S ^a   Nogueira, Carlos R A ^a   Vieira, Carlos M A G ^a   Sousa, Franscisca Cléa F ^a   Fonteles, Marta M F ^a   Viana, Glauce S B ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Behavioral studies; D2 like receptors; Haloperidol; Rat hippocampus and striatum

Indexed keywords

DOPAMINE 2 LIKE RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

BEHAVIOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; HIPPOCAMPUS; LOCOMOTION; MALE; NONHUMAN; PARAMETER; RAT; RECEPTOR DENSITY; UPREGULATION;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0038295876     PISSN: 03766357     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-6357(03)00028-7     Document Type: Article

References (34)

1. Ahlenius S., Hillegaart V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol. Biochem. Behav. 24:1986;1409-1415.
2. Bardgett M.E., Henry J.D. Locomotor activity and accumbens Fos expression driven by ventral hippocampal stimulation require D1 and D2 receptors. Neuroscience. 94:1999;59-70.
3. Barnes D.E., Robinson B., Csernansky J.G., Bellows E.P. Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants. Pharmacol. Biochem. Behav. 36:1990;883-887.
4. Besret L., Page K.J., Dunnet S.B. The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after sub-chronic administration and wash-out of haloperidol in the rat. Brain Res. 853:2000;125-135.
5. Brenner D.M., Bardgett M.E. Haloperidol blocks increased locomotor activity elicited by carbachol infusion into the ventral hippocampal formation. Pharmacol. Biochem. Behav. 60:1998;759-764.
6. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding: clinical and pharmacology potencies of antischizophrenic drugs. Science. 192:1976;481-483.
7. Davidkova G., Zhou L.W., Morabito M., Zhang S.P., Weiss B. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of DA dopamine-mediated behaviors without causing up-regulation of D2 dopamine receptors. J. Pharmacol. Exp. Ther. 285:1998;1187-1196.
8. De Graaf C.J., Korf J. Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity. Psychopharmacology. 90:1986;54-57.
9. Ellenbroek B.A., Artz M.T., Cools A.R. The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur. J. Pharmacol. 196:1991;103-108.
10. Fleminger S., Rupniak N.M., Hall M.D., Jenner P., Marsden C.D. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. Biochem. Pharmacol. 32:1983;2921-2927.
11. Hartgraves S.L., Kelly P.H. Role of mesencephalic reticular formation in cholinergic-induced catalepsy and anticholinergic reversal of neuroleptic-induced catalepsy. Brain Res. 307:1984;47-54.
12. Jenner, P., Kerwin, R., Rupniak, N.M.J., Murugaiah, K., Hall, M.D., Fleminger, S., Marsden, C.D., 1983. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. J. Neurol. Transm. 18 (Suppl. 18), 205-212.
13. Jorgensen H.A., Andreassen O.A., Hole K. The relationship between motor effects in rats following acute and chronic haloperidol treatment. Psychopharmacology. 116:1994;89-92.
14. 125I ] Epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors Life Sci. 49:1991;617-618.
15. Kinon B.J., Kane J.M. Difference in catalepsy response in inbred rats during chronic holoperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops. Psychopharmacology. 98:1989;465-471.
16. Laruelle M., Jaskiw G.E., Lipska B.K., Kolachana B., Casanova M.F., Kleinman J.E., Weinberger D.R. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res. 575:1992;47-56.
17. Liegeois J., Ichikawa J., Meltzer H. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947:2002;157-165.
18. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
19. Mandhane S.N., Chopde C.T., Ghosh A.K. Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 328:1997;135-141.
20. Marin C., Chase T.N. Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. Eur. J. Pharmacol. 231:1993;191-196.
21. Mileson B.E., Lewis M.H., Mailman R.B. Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain Res. 561:1991;1-10.
22. Ossowska K., Karez M., Wardas J., Wolfarth S. Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy. Eur. J. Pharmacol. 182:1990;327-334.
23. Ossowska K., Pietraszek M., Wardas J., Nowak G., Wolfarth S. Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn Schmiedebergs. Arch. Pharmacol. 359:1999;280-287.
24. Patacchioli F.R., Di Grezia R., Angelucci L. Arginine-aspartate and haloperidol-induced neurobehavioral effects in the rat. Eur. J. Pharmacol. 299:1996;29-32.
25. Potter, W.Z., Hollister, L.E., 1998. Antipsychotic agents & lithium. In: Katzung, B.G. (Ed.), Basic e Clinical Pharmacology, Seventh ed. Appleton & Lange, East Norwalk, Connecticut, USA, pp. 464-482.
26. Rang, H.P., Dale, M.M., Ritter, J.M., Gardner, P., 2001. Pharmacology. Churchill Livinstone, Philadelphia, USA, 839 pp.
27. Ritter L.M., Meador-Woodruff J.H. Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression. Biol. Psychiatry. 42:1997;155-164.
28. Schroder U., Schroder H., Augustin W., Sabel B.A. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding. J. Pharmacol. Exp. Ther. 271:1994;1193-1196.
29. Siegel S.J., Winey K.I., Gur R.E., Lenox R.H., Bilker W.B., Ikeda D., Gandhi N., Zhang W.X. Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology. 26:2002;817-823.
30. Vanover K.E. Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice. Psychopharmacology. 136:1998;123-131.
31. Vital M.A.B.F., Flório J.C., Frussa-Filho R., De Lucia R., Tufik S., Palermo-Neto J. Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover. Life Sci. 62:1998;1161-1169.
32. Watanabe M., Ohtakeno S., Watanabe H., Mamiya G., Ichinowatari N. Effects of long-term treatment of haloperidol on D2 dopamine receptors in various areas of rat brain. Yakubutsu Seishin Kodo. 13:1993;315-319.
33. Westerink B.H.C., Kawahara Y., Boer P.D., Geels C., Vries J.B.D., Wikström H.V., Kalkeren A.V., Vliet B.V., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 412:2001;127-138.
34. Yu J., Kallstrom L., Wiesel F.A., Johnson A.E. Neurochemical changes in the entopeduncular nucleus and increased oral behavior in rats treated subchronically with clozapine or haloperidol. Synapse. 34:1999;192-207.